← Browse by Condition
Medical Condition

thyroid eye disease ted

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 3, Phase 1

ClinicalMetric tracks all active clinical trials for thyroid eye disease ted sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1
1
Phase 3
1
Top Sponsors
Zai Lab (Shanghai) Co., Ltd. 1 trial
Changchun GeneScience Pharmaceutical Co., Ltd. 1 trial
Taipei Veterans General Hospital, Taiwan 1 trial

Recruiting Clinical Trials

NCT07211776 Phase 3
Recruiting

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

Enrollment
99 pts
Location
China
Sponsor
Zai Lab (Shanghai) Co., Ltd.
View Trial →
NCT06569758 Phase 1
Recruiting

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

Enrollment
76 pts
Location
China
Sponsor
Changchun GeneScience Pharmace...
View Trial →
NCT07400757
Recruiting

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

Enrollment
120 pts
Location
Taiwan
Sponsor
Taipei Veterans General Hospit...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology